Markovic, J
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: A phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Small number of research groups : A limited number of research groups have conducted most studies, which may affect the generalizability of the results
Clinical studies document sustained improvements over extended use
K-means clustering of amplicon sequence variant data confirmed that 5-Amino-1MQ treatment generated a distinct cecal microbiome profile from all other treatment groups including diet-switched vehicle controls indicating that NNMT inhibition produces microbiome changes that are separable from those produced by dietary composition alone
Bock-Marquette, I., Saxena, A., White, M